Basic Information
RNALocate ID: | RLID-D:11000687 |
RNA Symbol: | hsa-miR-502-3p |
Localization: | Microvesicle |
RNA Information
RNA Name: | hsa-miR-502-3p |
RNA ID: | miRBase:MIMAT0004775 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
Tissue/Cell Line: | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells |
Database: | EVmiRNA |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002670 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01002671 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:11003989 | Exosome | B cell line (Raji)|Primary dendritic cells | 21505438 |
RLID:11003990 | Exosome | Plasma | 23663360 |
RLID:11003991 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11003992 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11003993 | Microvesicle | Plasma | 23077538 |
RLID:11003994 | Microvesicle | Seminal plasma | 23539611 |
RLID-D:11000207 | Exosome | Blood |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-502-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-55601 |
MNDR | hsa-miR-502-3p | Ovarian clear cell carcinoma | MNDR-E-MI-55602 |
MNDR | hsa-miR-502-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-55603 |
MNDR | hsa-miR-502-3p | Lymphoma | MNDR-E-MI-55604 |
MNDR | hsa-miR-502-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-55605 |
MNDR | hsa-miR-502-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-55606 |
MNDR | hsa-miR-502-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-55607 |
MNDR | hsa-miR-502-3p | Her2-receptor positive breast cancer | MNDR-E-MI-55608 |
MNDR | hsa-miR-502-3p | Chronic lymphocytic leukemia | MNDR-E-MI-55609 |
MNDR | hsa-miR-502-3p | Gastric cancer | MNDR-E-MI-55610 |
MNDR | hsa-miR-502-3p | Alzheimer disease | MNDR-E-MI-55611 |
MNDR | hsa-miR-502-3p | Bladder cancer | MNDR-E-MI-55612 |
MNDR | hsa-miR-502-3p | Esophageal carcinoma | MNDR-E-MI-55613 |
MNDR | hsa-miR-502-3p | Dysautonomia familial | MNDR-E-MI-55614 |
MNDR | hsa-miR-502-3p | Seizures | MNDR-E-MI-55615 |
MNDR | hsa-miR-502-3p | Cardiovascular disease | MNDR-E-MI-55616 |
MNDR | hsa-miR-502-3p | Lung cancer | MNDR-E-MI-55617 |
MNDR | hsa-miR-502-3p | Parkinson disease | MNDR-E-MI-55618 |
MNDR | hsa-miR-502-3p | Breast cancer | MNDR-E-MI-55619 |
MNDR | hsa-miR-502-3p | Pancreatic cancer | MNDR-E-MI-55620 |
MNDR | hsa-miR-502-3p | Nephroblastoma | MNDR-E-MI-55621 |
MNDR | hsa-miR-502-3p | Colon cancer | MNDR-E-MI-55622 |
MNDR | hsa-miR-502-3p | Familial ovarian cancer | MNDR-E-MI-55623 |
MNDR | hsa-miR-502-3p | Kidney cancer | MNDR-E-MI-55624 |
MNDR | hsa-miR-502-3p | Glioblastoma | MNDR-E-MI-55625 |
MNDR | hsa-miR-502-3p | Astrocytoma | MNDR-E-MI-55626 |
MNDR | hsa-miR-502-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-55627 |
MNDR | hsa-miR-502-3p | Gastric adenocarcinoma | MNDR-E-MI-55628 |
MNDR | hsa-miR-502-3p | Cervical squamous cell carcinoma | MNDR-E-MI-55629 |
MNDR | hsa-miR-502-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-55630 |
MNDR | hsa-miR-502-3p | Lung squamous cell carcinoma | MNDR-E-MI-55631 |
MNDR | hsa-miR-502-3p | Lung adenocarcinoma | MNDR-E-MI-55632 |
MNDR | hsa-miR-502-3p | Adrenocortical carcinoma | MNDR-E-MI-55633 |
MNDR | hsa-miR-502-3p | Thyroid carcinoma | MNDR-E-MI-55634 |
MNDR | hsa-miR-502-3p | Ovarian carcinoma | MNDR-E-MI-55635 |
MNDR | hsa-miR-502-3p | Bladder urothelial carcinoma | MNDR-E-MI-55636 |
MNDR | hsa-miR-502-3p | Pancreatic adenocarcinoma | MNDR-E-MI-55637 |
MNDR | hsa-miR-502-3p | Carcinoma renal cell | MNDR-E-MI-55638 |
MNDR | hsa-miR-502-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-55639 |
MNDR | hsa-miR-502-3p | Renal clear cell carcinoma | MNDR-E-MI-55640 |
MNDR | hsa-miR-502-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-55641 |
MNDR | hsa-miR-502-3p | Hepatocellular carcinoma | MNDR-E-MI-55642 |
MNDR | hsa-miR-502-3p | Familiar ovarian carcinoma | MNDR-E-MI-55643 |
MNDR | hsa-miR-502-3p | B-cell lymphoma | MNDR-E-MI-55644 |
MNDR | hsa-miR-502-3p | Rheumatoid arthritis | MNDR-E-MI-55645 |
MNDR | hsa-miR-502-3p | Retinoblastoma | MNDR-E-MI-55646 |
MNDR | hsa-miR-502-3p | Hodgkin lymphoma | MNDR-E-MI-55647 |
MNDR | hsa-miR-502-3p | Crohn disease | MNDR-E-MI-55648 |
MNDR | hsa-miR-502-3p | Neuromyelitis optica | MNDR-E-MI-55649 |
MNDR | hsa-miR-502-3p | Colorectal cancer | MNDR-E-MI-55650 |
MNDR | hsa-miR-502-3p | Nasopharynx carcinoma | MNDR-E-MI-55651 |
MNDR | hsa-miR-502-3p | Ependymoma | MNDR-E-MI-55652 |
MNDR | hsa-miR-502-3p | Nasopharyngeal cancer | MNDR-E-MI-55653 |
MNDR | hsa-miR-502-3p | Hypersomnolence idiopathic | MNDR-E-MI-55654 |
MNDR | hsa-miR-502-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-55655 |
MNDR | hsa-miR-502-3p | Stroke lacunar | MNDR-E-MI-55656 |
MNDR | hsa-miR-502-3p | Breast cancer her3+ negative | MNDR-E-MI-55657 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | B4GALT5 | Homo sapiens | RR00208370 |
TOP